- Cross reference: Picture is available at
http://www.presseportal.de/galerie.htx?type=obs -
Scientists from the College of Medicine at the Catholic
University of Korea have published newest data on the M2-PK test
from a multi-center study of colorectal cancer screening in the
journal ''Gut and Liver''. The results from cancer expert Professor
Yong Kim and his colleagues confirm the exceptionally high
capability of the M2-PK test, particularly in comparison to the
immunological fecal occult blood test (iFOBT), to detect adenomas and
colorectal cancer.
In their study Professor Kim and colleagues investigated the
enzymatic biomarker M2-PK with volunteers in patient groups with 139
cases of colorectal cancer and 124 with adenoma, along with a
population-based control group of 60 people, making a total of 323
subjects. The sensitivity of the M2-PK test was 92.8% for colorectal
cancer and 69.4% for adenomas. In addition, they also compared the
results of the M2-PK test with those of an immunological fecal
occult blood test (iFOBT). This was clearly inferiorto the M2-PK
test. The iFOBT detected only 47.5% of the colon cancers and just
12.1% of the adenomas. Consequently, the M2-PK test detected twice as
many colorectal cancer cases and nearly six times the number of
adenomas than the immunological fecal occult blood test (iFOBT).
These scientific results from the University of Korea categorically
confirm the capability of the fecal M2-PK test for screening and
early detection of colorectal cancer.
The fecal M2-PK test is available as a qualitative rapid test
under the name ScheBo® M2-PK QuickTM and as a fully quantitative
ELISA stool test.
Source: Kim YC, et al., Gut and Liver, online December 5th, 2014;
http://dx.doi.org/10.5009/gnl13457 , www.gutnliver.org/.
Contact:
ScheBo(.Biotech AG / Tel: +49-(0)641-4996-0 / Fax: +49-
(0)641-4996-78 www.schebo.com
